Search research articles
Contact Us
Filters
Showing results (41-50 of 51) with videos related to
Page
of 6
Sort By:
Blood
|
March 3, 2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma
Jennifer L Crombie, Sairah Ahmed, Matthew J Frigault, et al.
Blood Advances
|
October 31, 2025
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell Lymphoma
J Erika Haydu, Robert A Redd, Matthew M Lei, et al.
Transplantation and Cellular Therapy
|
October 20, 2021
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma
Reid W Merryman, Robert Redd, Erin Jeter, et al.
Blood Advances
|
April 3, 2025
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia
James T Yoon, Yinglu Zhou, Mariia Mikhaleva, et al.
Annals of Hematology
|
October 18, 2023
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
Reid W Merryman, Robert A Redd, Arnold S Freedman, et al.
Blood
|
April 7, 2019
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
Philippe Armand, Yi-Bin Chen, Robert A Redd, et al.
Blood
|
January 22, 2024
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, et al.
Blood Advances
|
November 18, 2022
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation
Reid W Merryman, Robert A Redd, Eleanor Taranto, et al.
Blood Advances
|
January 10, 2020
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
Matthew J Frigault, Philippe Armand, Robert A Redd, et al.
Haematologica
|
November 14, 2024
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers
Viktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 51) with videos related to
Sort By:
Page
of 6
Blood
|
March 3, 2026
Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma
Jennifer L Crombie, Sairah Ahmed, Matthew J Frigault, et al.
Blood Advances
|
October 31, 2025
A Retrospective Study of Treatment and Outcomes in Synchronous Systemic and Central Nervous System Large B-cell Lymphoma
J Erika Haydu, Robert A Redd, Matthew M Lei, et al.
Transplantation and Cellular Therapy
|
October 20, 2021
Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma
Reid W Merryman, Robert Redd, Erin Jeter, et al.
Blood Advances
|
April 3, 2025
Characteristics and outcomes of patients with double refractory and double exposed chronic lymphocytic leukemia
James T Yoon, Yinglu Zhou, Mariia Mikhaleva, et al.
Annals of Hematology
|
October 18, 2023
A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma
Reid W Merryman, Robert A Redd, Arnold S Freedman, et al.
Blood
|
April 7, 2019
PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation
Philippe Armand, Yi-Bin Chen, Robert A Redd, et al.
Blood
|
January 22, 2024
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy
Jennifer L Crombie, Tara Graff, Lorenzo Falchi, et al.
Blood Advances
|
November 18, 2022
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation
Reid W Merryman, Robert A Redd, Eleanor Taranto, et al.
Blood Advances
|
January 10, 2020
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation
Matthew J Frigault, Philippe Armand, Robert A Redd, et al.
Haematologica
|
November 14, 2024
Loncastuximab in high-risk and heavily pretreated relapsed/refractory diffuse large B-cell lymphoma: a realworld analysis from 21 US centers
Viktoriya Zelikson, Ashwath Gurumurthi, Yazeed Sawalha, et al.
Page
of 6